| pubmed-article:14506913 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14506913 | lifeskim:mentions | umls-concept:C1273518 | lld:lifeskim |
| pubmed-article:14506913 | lifeskim:mentions | umls-concept:C0014442 | lld:lifeskim |
| pubmed-article:14506913 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:14506913 | lifeskim:mentions | umls-concept:C0015684 | lld:lifeskim |
| pubmed-article:14506913 | lifeskim:mentions | umls-concept:C0002488 | lld:lifeskim |
| pubmed-article:14506913 | lifeskim:mentions | umls-concept:C1172779 | lld:lifeskim |
| pubmed-article:14506913 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:14506913 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:14506913 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:14506913 | lifeskim:mentions | umls-concept:C0211726 | lld:lifeskim |
| pubmed-article:14506913 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:14506913 | pubmed:dateCreated | 2003-9-24 | lld:pubmed |
| pubmed-article:14506913 | pubmed:abstractText | Arachidonoyl-serotonin inhibits in a mixed-type manner the metabolism of the endocannabinoid anandamide by the enzyme fatty acid amidohydrolase. In the present study, compounds related to arachidonoyl-serotonin have been synthesised and investigated for their ability to inhibit anandamide hydrolysis by this enzyme in rat brain homogenates. Removal of the 5-hydroxy from the serotonin head group of arachidonoyl-serotonin produced a compound (N-arachidonoyltryptamine) that was a 2.3-fold weaker inhibitor of anandamide hydrolysis, but which also produced its inhibition by a mixed-type manner (Ki(slope) 1.3 microM; Ki(intercept) 44 microM). Replacement of the amide linkage in this compound by an ester group further reduced the potency. In contrast, replacement of the arachidonoyl side chain by a linolenoyl side chain did not affect the observed potency. N-(Fur-3-ylmethyl) arachidonamide (UCM707), N-(fur-3-ylmethyl)linolenamide and N-(fur-3-ylmethyl)oleamide inhibited anandamide hydrolysis with pI50 values of 4.53, 5.36 and 5.25, respectively. The linolenamide derivative was also found to be a mixed-type inhibitor. It is concluded that the 5-hydroxy group of arachidonoyl-serotonin contributes to, but is not essential for, inhibitory potency at fatty acid amidohydrolase. | lld:pubmed |
| pubmed-article:14506913 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14506913 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14506913 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14506913 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:14506913 | pubmed:issn | 1475-6366 | lld:pubmed |
| pubmed-article:14506913 | pubmed:author | pubmed-author:RamosJosé AJA | lld:pubmed |
| pubmed-article:14506913 | pubmed:author | pubmed-author:FowlerChristo... | lld:pubmed |
| pubmed-article:14506913 | pubmed:author | pubmed-author:López-Rodrígu... | lld:pubmed |
| pubmed-article:14506913 | pubmed:author | pubmed-author:Ortega-Gutiér... | lld:pubmed |
| pubmed-article:14506913 | pubmed:author | pubmed-author:VisoAlmaA | lld:pubmed |
| pubmed-article:14506913 | pubmed:author | pubmed-author:TigerGunnarG | lld:pubmed |
| pubmed-article:14506913 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14506913 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:14506913 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14506913 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14506913 | pubmed:pagination | 225-31 | lld:pubmed |
| pubmed-article:14506913 | pubmed:dateRevised | 2007-3-21 | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:meshHeading | pubmed-meshheading:14506913... | lld:pubmed |
| pubmed-article:14506913 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14506913 | pubmed:articleTitle | Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. | lld:pubmed |
| pubmed-article:14506913 | pubmed:affiliation | Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 87 Umeå, Sweden. cf@pharm.umu.se | lld:pubmed |
| pubmed-article:14506913 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14506913 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:29347 | entrezgene:pubmed | pubmed-article:14506913 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:14506913 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14506913 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14506913 | lld:pubmed |
